Digital gene expression analysis of the pathogenesis and therapeutic mechanisms of ligustrazine and puerarin in rat atherosclerosis

Gene

Volumn 552, Issue 1, 2014, Pages 75-80

  Fu, Rao ^a   Zhang, Yuting ^a   Guo, Yiran ^a   Zhang, Yanling ^b   Xu, Ying ^a   Chen, Fang ^a  

^a SICHUAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Atherosclerosis; Digital gene expression; Ligustrazine; Pathogenesis; Puerarin

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PUERARIN; TETRAMETHYLPYRAZINE; ISOFLAVONE DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; GENE EXPRESSION; GENE MAPPING; GENE ONTOLOGY; GENE SEQUENCE; MALE; METABOLISM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; RAT; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; GENETICS; WISTAR RAT;

RATTUS;

ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION; GENE ONTOLOGY; ISOFLAVONES; MALE; METABOLIC NETWORKS AND PATHWAYS; OXIDATIVE PHOSPHORYLATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PYRAZINES; RATS; RATS, WISTAR;

EID: 84907991371     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.09.015     Document Type: Article

References (24)

1. Ansorge W.J. Next-generation DNA sequencing techniques. New Biotechnol. 2009, 25:195-203.
2. Auclair S., Milenkovic D., Besson C., Chauvet S., Gueux E., Morand C., Mazur A., Scalbert A. Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 2009, 204:e21-e27.
3. Audic S., Claverie J.M. The significance of digital gene expression profiles. Genome Res. 1997, 7:986-995.
4. Bennett S.T., Barnes C., Cox A., Davies L., Brown C. Toward the 1000 dollars human genome. Pharmacogenomics 2005, 6:373-382.
5. Gouni-Berthold I., Giannakidou E., Faust M., Berthold H.K., Krone W. Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with Type 2 diabetes mellitus. Diabet. Med. 2006, 23:419-425.
6. Hegele R.A., Al-Shali K.Z., House A.A., Hanley A.J., Harris S.B., Mamakeesick M., Fenster A., Zinman B., Cao H., Spence J.D. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke 2005, 36:2566-2570.
7. Hsueh W.A., Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1891-1895.
8. Jiang F., Qian J., Chen S., Zhang W., Liu C. Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress. Pharm. Biol. 2011, 49:856-863.
9. Kanter J.E., Kramer F., Barnhart S., Averill M.M., Vivekanandan-Giri A., Vickery T., Li L.O., Becker L., Yuan W., Chait A., Braun K.R., Potter-Perigo S., Sanda S., Wight T.N., Pennathur S., Serhan C.N., Heinecke J.W., Coleman R.A., Bornfeldt K.E. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E715-E724.
10. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
11. Miyazaki A., Sakashita N., Lee O., Takahashi K., Horiuchi S., Hakamata H., Morganelli P.M., Chang C.C., Chang T.Y. Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1568-1574.
12. Morello F., de Bruin T.W., Rotter J.I., Pratt R.E., van der Kallen C.J., Hladik G.A., Dzau V.J., Liew C.C., Chen Y.D. Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2149-2154.
13. Mzhavia N., Yu S., Ikeda S., Chu T.T., Goldberg I., Dansky H.M. Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice. Diabetes 2008, 57:2774-2783.
14. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7614-7619.
15. Shi W.G., Qu L., Wang J.W. Study on interventing effect of puerarin on insulin resistance in patients with coronary heart disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002, 22:21-24.
16. Sliskovic D.R., White A.D. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 1991, 12:194-199.
17. Subramanian R., Ramaswamy M., Wasan K.M. Role of lipid and lipoprotein metabolizing enzymes in the development of atherosclerosis. Indian J. Exp. Biol. 2003, 41:14-25.
18. Sutter M.C., Wang Y.X. Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc. Res. 1993, 27:1891-1901.
19. Tang Q., Ma X., Mo C., Wilson I.W., Song C., Zhao H., Yang Y., Fu W., Qiu D. An efficient approach to finding Siraitia grosvenorii triterpene biosynthetic genes by RNA-seq and digital gene expression analysis. BMC Genomics 2011, 12:343.
20. Wu Y., Li J., Wang J., Si Q., Zhang J., Jiang Y., Chu L. Anti-atherogenic effects of centipede acidic protein in rats fed an atherogenic diet. J. Ethnopharmacol. 2009, 122:509-516.
21. Xiao S., Mo D., Wang Q., Jia J., Qin L., Yu X., Niu Y., Zhao X., Liu X., Chen Y. Aberrant host immune response induced by highly virulent PRRSV identified by digital gene expression tag profiling. BMC Genomics 2010, 11:544.
22. Yan L.P., Chan S.W., Chan A.S., Chen S.L., Ma X.J., Xu H.X. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci. 2006, 79:324-330.
23. Zapolska-Downar D., Zapolski-Downar A. Atherosclerosis: a chronic inflammatory diseases. Przegl. Lek. 2002, 59:147-152.
24. Zhu X.Y., Li P., Yang Y.B., Liu M.L. Xuezhikang, extract of red yeast rice, improved abnormal hemorheology, suppressed caveolin-1 and increased eNOS expression in atherosclerotic rats. PLoS One 2013, 8:e62731.